Comparison of Acarbose and Voglibose in Diabetes Patients Who Are Inadequately Controlled with Basal Insulin Treatment: Randomized, Parallel, Open-Label, Active-Controlled Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- JOURNAL OF KOREAN MEDICAL SCIENCE29(1) · pp.90 · 2014
- 피인용
- Web of Science 50KCI 1
- JCR IF
- JCR 2013 1.253
- ISSN
- 1011-8934
저자
- 이미영연세대학교
- 최동섭교신저자고려대학교
- 이문규성균관대학교
- 이형우영남대학교
- 박태선전북대학교
- 김두만한림대학교
- 김인주부산대학교
- 장학철서울대학교
- 박용수한양대학교
- 권혁상가톨릭대학교
- 이승훈가톨릭대학교
- 정춘희연세대학교
- 김덕규동아대학교
- 신희강Bayer Korea Ltd.
초록
We studied the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetes patients whose blood glucose levels were inadequately controlled with basal insulin alone or in combination with metformin (or a sulfonylurea). This study was a 24-week prospective, open-label, randomized, active-controlled multi-center study. Participants were randomized to receive either acarbose (n= 59, 300 mg/day) or voglibose (n = 62, 0.9 mg/day). The mean HbA(1c) at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose (from 8.43% +/- 0.71% to 7.71% +/- 0.93%) and voglibose groups (from 8.38% +/- 0.73% to 7.68% +/- 0.94%). The mean fasting plasma glucose level and self-monitoring of blood glucose data from 1 hr before and after each meal were significantly decreased at week 24 in comparison to baseline in both groups. The levels 1 hr after dinner at week 24 were significantly decreased in the acarbose group (from 233.54 +/- 69.38 to 176.80 +/- 46.63 mg/dL) compared with the voglibose group (from 224.18 +/- 70.07 to 193.01 +/- 55.39 mg/dL). In conclusion, both acarbose and voglibose are efficacious and safe in patients with type 2 diabetes who are inadequately controlled with basal insulin.
키워드
Diabetes Mellitus, Type 2AcarboseVogliboseIMPAIRED GLUCOSE-TOLERANCEGLYCEMIC CONTROLPOSTPRANDIAL HYPERGLYCEMIACARDIOVASCULAR BENEFITS24-WEEK MONOTHERAPYCONTROLLED-TRIALNIDDM PATIENTSWEIGHT-GAINGLARGINEEFFICACY
식별자
- WoS UID
- 000330508600014
- KCI
- ART001844603



로그인
연구물 목록으로